Publication date: Dec 05, 2024
In 2019, coronavirus disease 2019 (COVID-19) started a global health crisis and was associated with high rates of depression and anxiety. Both mental disorders and COVID-19 exhibit similarities in pathophysiology, characterized by immune system overactivation, involvement of the purinergic system, and oxidative stress, besides additional factors and systems likely contributing to the complexities of these conditions. The purinergic system contributes to the disease-influenced immune response, an essential strategy for controlling pathophysiological effects. In this context, the hormone melatonin emerges as a substance that can modulate the purinergic system and contribute positively to the pathophysiology of SARS-CoV-2 infection and associated mental disorders. Melatonin is a hormone that regulates the body’s circadian rhythms, plays an essential role in regulating sleep and mood, and modulates the purinergic system. Recent studies suggest melatonin’s anti-inflammatory and antioxidant properties may benefit COVID-19. This review explores melatonin’s impact on inflammatory cytokine storm in COVID-19 through purinergic system modulation.
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Melatonin |
| disease | MESH | Cytokine Storm |
| disease | MESH | COVID-19 |
| disease | MESH | depression |
| disease | MESH | anxiety |
| disease | MESH | mental disorders |
| pathway | REACTOME | Immune System |
| disease | MESH | oxidative stress |
| disease | IDO | immune response |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | IDO | role |